Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Jocelyn Zhou"'
Publikováno v:
Clinical Pharmacokinetics. 57:855-866
Pasireotide (SOM230, Signifor®) is a somatostatin analog approved in a subcutaneous formulation for the treatment of Cushing’s disease. This analysis characterizes the population pharmacokinetics (PopPK) of subcutaneous pasireotide jointly in heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b69b3d3c045ccab99dbc2093d45b174
https://doi.org/10.1007/s40262-017-0600-y
https://doi.org/10.1007/s40262-017-0600-y
Autor:
Mateva Liudmila, Corinne Emotte, George Golor, Richard A. Preston, Yves Horsmans, Henry Castro, Jocelyn Zhou, Oren Shibolet, Dalila Sellami, Michelle Quinlan, Hildegard Boss
Publikováno v:
Clinical Pharmacokinetics. 57:345-354
Sonidegib is a potent, selective and orally bioavailable inhibitor of the Hedgehog signaling pathway, primarily metabolized by the liver. In order to make dose recommendations for patients with hepatic impairment, we have assessed here the pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05a52c1fecab7d250f30050898e6af21
https://doi.org/10.1007/s40262-017-0560-2
https://doi.org/10.1007/s40262-017-0560-2
Publikováno v:
The Journal of Clinical Pharmacology. 56:1406-1415
Sonidegib selectively inhibits smoothened protein, suppresses the growth of Hedgehog pathway-dependent tumors, and has recently been approved in the indication of locally advanced basal cell carcinoma. A comprehensive exposure-response analysis was c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85a95eb5c5cbd598aa8adb3809a9e0ef
https://doi.org/10.1002/jcph.749
https://doi.org/10.1002/jcph.749
Publikováno v:
European Journal of Clinical Pharmacology. 72:1427-1432
Sonidegib prevents activation of the Hedgehog signal transduction pathway. This PK-QT analysis has been performed to test for potential prolongation of the QT/QTc interval during extended use, and to understand the exposure-QT relationship for sonide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f5db00b55bd575aaa320a632ee7e383
https://doi.org/10.1007/s00228-016-2128-8
https://doi.org/10.1007/s00228-016-2128-8
Autor:
Michelle Quinlan, Franck Picard, Dalila Sellami, Hildegard Boss, Jocelyn Zhou, Henry Castro, Kelli J Glenn
Publikováno v:
British Journal of Clinical Pharmacology. 82:1022-1029
Aims This study aimed to evaluate the impact of esomeprazole on the pharmacokinetics of sonidegib. Methods This Phase I study evaluated the impact of the proton pump inhibitor (PPI) esomeprazole on the oral absorption and pharmacokinetics (PKs) of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a67a37c060160d7cc0717ecd9e70a94c
https://doi.org/10.1111/bcp.13038
https://doi.org/10.1111/bcp.13038
Autor:
Jerry Nedelman, Ovidiu Chiparus, Pai-Hsi Huang, Dalila Sellami, Eunju Hurh, Andrew M. Stein, Varun Goel, Jocelyn Zhou, Sven Gogov
Publikováno v:
Cancer Chemotherapy and Pharmacology. 77:745-755
Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::148374bb6cfc14906e789f31fe6d5dcb
https://doi.org/10.1007/s00280-016-2982-1
https://doi.org/10.1007/s00280-016-2982-1
Autor:
Ruth Plummer, Martin Kaatz, Alexander Guminski, Patrick Combemale, Karl D. Lewis, Ragini R. Kudchadkar, Manisha Mone, Dalila Sellami, Jocelyn Zhou, Carmen Loquai, Luc Dirix, Anne Lynn S. Chang, Ralf Gutzmer, John T. Lear, Tingting Yi, Michael R. Migden, Reinhard Dummer, Alexandros Stratigos, Uwe Trefzer, Henry Castro
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Background Patients with locally advanced basal cell carcinoma (laBCC) or metastatic BCC (mBCC), two difficult-to-treat populations, have had limited treatment options. Sonidegib, a hedgehog pathway inhibitor (HPI), was approved in laBCC based on res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2c71a42ca781cb5725f0ad8c828de1c
https://www.zora.uzh.ch/id/eprint/143585/
https://www.zora.uzh.ch/id/eprint/143585/
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 45(4)
Sonidegib (Odomzo®) is an orally available Smoothened inhibitor for the treatment of advanced basal cell carcinoma. Sonidegib was found to be metabolized primarily by cytochrome P450 (CYP)3A in vitro. The effect of multiple doses of the strong CYP3A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19413d02d53b18c1ea6a8a9c3fe17ae9
https://pubmed.ncbi.nlm.nih.gov/28122787
https://pubmed.ncbi.nlm.nih.gov/28122787
Publikováno v:
Journal of clinical pharmacology. 56(11)
Sonidegib selectively inhibits smoothened protein, suppresses the growth of Hedgehog pathway-dependent tumors, and has recently been approved in the indication of locally advanced basal cell carcinoma. A comprehensive exposure-response analysis was c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::075df2941decc9eb7406366dc1d6e833
https://pubmed.ncbi.nlm.nih.gov/27095306
https://pubmed.ncbi.nlm.nih.gov/27095306
Autor:
Jocelyn, Zhou, Michelle, Quinlan, Kelli, Glenn, Hildegard, Boss, Franck, Picard, Henry, Castro, Dalila, Sellami
Publikováno v:
British journal of clinical pharmacology. 82(4)
This study aimed to evaluate the impact of esomeprazole on the pharmacokinetics of sonidegib.This Phase I study evaluated the impact of the proton pump inhibitor (PPI) esomeprazole on the oral absorption and pharmacokinetics (PKs) of a single dose of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::87e1e7ea4b7ed1a5ff365dc931ddcc49
https://pubmed.ncbi.nlm.nih.gov/27277189
https://pubmed.ncbi.nlm.nih.gov/27277189